Results 1 to 10 of about 3,108,020 (210)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma

International Journal of Molecular Sciences, 2022
Therapeutic options for treating advanced melanoma have progressed rapidly in recent decades. Until 6 years ago, the regimen for treating advanced melanoma consisted mainly of cytotoxic agents such as dacarbazine and type I interferons.
Taku Fujimura, Yusuke Muto, Yoshihide Asano   +2 more
exaly   +2 more sources

Long-Term Survival in Patients With Advanced Melanoma.

JAMA Netw Open
This cohort study evaluates long-term survival in patients with advanced melanoma treated with immune checkpoint inhibitors outside clinical trials.
van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot J W B JW, Hospers GAP, Kapiteijn E, Leeneman B, D P, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM.   +20 more
europepmc   +2 more sources

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion.
H. Tawbi, D. Schadendorf, E. Lipson, P. Ascierto, L. Matamala, E. Castillo Gutiérrez, P. Rutkowski, H. Gogas, C. Lao, J. J. de Menezes, S. Dalle, A. Arance, J. Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, S. Keidel, K. Simonsen, A.M. Sobiesk, Bin Li, F. Hodi, G. Long   +21 more
semanticscholar   +1 more source

More than Just Skin-Deep: A Review of Imaging’s Role in Guiding CAR T-Cell Therapy for Advanced Melanoma

Diagnostics, 2023
Advanced melanoma is one of the deadliest cancers, owing to its invasiveness and its propensity to develop resistance to therapy. Surgery remains the first-line treatment for early-stage tumors but is often not an option for advanced-stage melanoma ...
Conor M. Prendergast, Kathleen M. Capaccione, Egesta Lopci, Jeeban P. Das, Alexander N. Shoushtari, Randy Yeh, Daniel Amin, Laurent Dercle, Dorine De Jong   +8 more
doaj   +1 more source

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2021
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, T. Bas, C. Ritchings, J. Larkin, F. Hodi   +28 more
semanticscholar   +1 more source

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

New England Journal of Medicine, 2023
BACKGROUND Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage
S. Patel, M. Othus, Yuanbin Chen, G. Wright, K. Yost, John R Hyngstrom, S. Hu-Lieskovan, C. Lao, L. Fecher, T. Truong, Jennifer Eisenstein, S. Chandra, J. A. Sosman, K. Kendra, Richard C Wu, C. Devoe, G. Deutsch, A. Hegde, M. Khalil, Ankit Mangla, A. Reese, M. Ross, A. Poklepovic, G. Phan, A. Onitilo, Demet Yaşar, Benjamin Powers, G. Doolittle, G. In, Niels Kokot, G. Gibney, M. Atkins, M. Shaheen, J. Warneke, A. Ikeguchi, J. E. Najera, B. Chmielowski, J. Crompton, J. Floyd, E. Hsueh, K. Margolin, W. Chow, K. Grossmann, E. Dietrich, V. Prieto, M. Lowe, E. Buchbinder, John M. Kirkwood, L. Korde, J. Moon, E. Sharon, V. Sondak, A. Ribas   +52 more
semanticscholar   +1 more source

Treatment of Advanced Melanoma: Past, Present and Future

Life, 2020
Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons.
Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba   +4 more
doaj   +1 more source

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing, Mingyi Jing, Yi Cai, Jing Shi, Xufan Zhang, Baohua Zhu, Baohua Zhu, Fan Yuan, Fan Yuan, Jie Zhang, Jie Zhang, Min Xiao, Mingling Chen   +12 more
doaj   +1 more source

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma

Journal of Ophthalmic & Vision Research, 2022
The management of conjunctival melanoma is challenging due to the more frequent local recurrence and metastasis compared to other conjunctival neoplasms.
Ho-Seok Sa, Claire Daniel, Bita Esmaeli
doaj   +1 more source

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

New England Journal of Medicine, 2022
BACKGROUND Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit.
M. Rohaan, T. H. Borch, J. H. van den Berg, Ö. Met, R. Kessels, M. G. Geukes Foppen, J. Stoltenborg Granhøj, B. Nuijen, C. Nijenhuis, I. Jedema, M. van Zon, Saskia Scheij, J. Beijnen, Marten Hansen, C. Voermans, I. M. Noringriis, T. Monberg, R. Holmstroem, L. Wever, M. V. VAN DIJK, L. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, M. Karger, J. Borgers, Renske M T ten Ham, V. Retèl, W. V. van Harten, F. Lalezari, H. van Tinteren, A. V. D. van der Veldt, G. Hospers, Marion A. Stevense-den Boer, K. Suijkerbuijk, M. Aarts, D. Piersma, A. van den Eertwegh, J. D. de Groot, G. Vreugdenhil, E. Kapiteijn, M. Boers-Sonderen, W. Fiets, F. van den Berkmortel, E. Ellebaek, L. Hölmich, A. V. Van Akkooi, W. V. van Houdt, M. Wouters, J. V. van Thienen, C. Blank, A. Meerveld-Eggink, S. Klobuch, S. Wilgenhof, T. Schumacher, M. Donia, I. Svane, J. Haanen   +56 more
semanticscholar   +1 more source